Product Description
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Canertinib)
Mechanisms of Action: ERBB2 Inhibitor,EGFR Inhibitor,ERBB4 Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer
Phase 1: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00051051 | P2 |
Completed |
Breast Cancer |
None |
|
| A4161003 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
None |
|
| A4161001 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
None |